How did Pfizer's revenue perform in the third quarter and year-to-date?

Pfizer reported a 9% increase in revenues to $12.28 billion for the third quarter ended October 1, 2006, and a 3% increase to $35.77 billion for the first nine months of 2006 compared to the same periods in 2005. This growth was largely driven by the Pharmaceutical segment.

What is the impact of major product patent expirations on Pfizer's revenue?

Pfizer is experiencing revenue declines from major products losing U.S. exclusivity, such as Zoloft and Zithromax, which negatively impacted revenues. However, the company is mitigating these effects through the strong performance of its in-line products (like Lipitor and Celebrex) and new product launches (like Chantix and Sutent).

What are the key strategic initiatives Pfizer is undertaking?

Pfizer is undertaking two major strategic initiatives: the planned divestiture of its Consumer Healthcare business for approximately $16.6 billion, and the ongoing 'Adapting to Scale' productivity initiative focused on improving efficiency and reducing costs across the organization. These actions are aimed at optimizing the company's structure and financial performance.

How is Pfizer managing its cost structure and productivity?

The 'Adapting to Scale' initiative is central to Pfizer's cost management strategy. This program aims to achieve significant annual cost savings by reorganizing R&D, optimizing manufacturing, standardizing processes, and reducing operational expenses. The company reported exceeding its savings targets for 2006 and plans to further transform its cost structure in 2007 and 2008.

PFE 10-Q Filed Nov 3, 2006

Summary

Pfizer Inc. reported strong financial performance for the third quarter and first nine months of 2006, with notable revenue growth driven by its Pharmaceutical segment. Total revenues increased by 9% for the quarter and 3% year-to-date, reaching $12.28 billion and $35.77 billion, respectively. This growth was primarily fueled by key products like Lipitor, Celebrex, Lyrica, and Geodon, along with contributions from newly launched medicines, offsetting revenue declines from major products losing U.S. exclusivity. The company is actively managing its portfolio by divesting its Consumer Healthcare business, a significant strategic move expected to close by late 2006 for approximately $16.6 billion. This divestiture, along with ongoing productivity initiatives ('Adapting to Scale'), aims to streamline operations and improve cost efficiency. Despite challenges such as patent expirations and increased competition, Pfizer demonstrates a commitment to innovation through R&D investments and strategic acquisitions.

Key Highlights

1Revenues increased by 9% to $12.28 billion for the quarter and 3% to $35.77 billion year-to-date, driven by strong Pharmaceutical segment performance.
2Key growth drivers included Lipitor, Celebrex, Lyrica, and Geodon, alongside new product launches, which offset declines from products facing U.S. exclusivity loss.
3Pfizer announced an agreement to sell its Consumer Healthcare business for $16.6 billion, expected to close by late 2006.
4The company is aggressively pursuing cost savings through its 'Adapting to Scale' productivity initiative, exceeding savings targets.
5Net income more than doubled to $3.36 billion for the quarter and increased by 85% to $9.89 billion year-to-date.
6Diluted EPS rose to $0.46 for the quarter and $1.35 year-to-date, demonstrating improved profitability.
7Significant progress in managing tax provisions, including substantial benefits from tax settlements and regulatory changes.

PFIZER INC Quarterly Report for Q3 Ended Oct 1, 2006

Summary

Key Highlights

Frequently Asked Questions